News

In a decision made available on the 7th of November, Judge of the Supreme Court Luiz Fux dismissed a lawsuit by which … Supreme Court dismisses lawsuit against rule that guarantees a minimum term for patent protection

This Q&A gives a high level overview of trade mark disputes, including how trade mark infringement is assessed; unregistered trade marks; invalidation proceedings; … Trade mark Litigation in Brazil: Overview

As it is known, software protection follows the Copyright System, and a registration which is optional and of a declaratory nature can … New procedures regarding Software Registration in Brazil

Our partner Gabriel Leonardos and our lawyer Paulo Bianco published an article “When art is usable or wearable: works of applied art … When art is usable or wearable: works of applied art in the light of the Brazilian framework

Following the same strategy that has been adopted to deal with the current huge backlog of patent applications still awaiting examination, the BPTO launches one more alternative to accelerate examination of applications in areas considered strategic.

The Ministry of Environment published the Ordinance # 01/2017 on the Official Gazette of October 13, which establishes November 6th as the date when SISGEN (a database that will allow parties to register their ABS activities) will start to operate. Moreover, the same ordinance established November 6th as the beginning of the deadline provided by Brazilian Biodiversity Act (Law # 13.123/2015) for parties to regularize their ABS activities.

The NIC.br (Center of Information and Coordination of .BR), the Sentity responsible for implementing projects and decisions of the Brazilian Internet Steering Committee (CGI.br) by means of registering and maintaining domain names with the country code “.br”, has recently approved resolution CGI.br/RES/2017/031, which implements changes in the liberation process of domain names.

The Ministry of Environment published on its website the new templates of Benefit Sharing Agreements in compliance with the Biodiversity Act (Law # 13.123/2015). In light of such Act, the one who carries out activities of research and development accessing Brazilian genetic resources and traditional knowledge must share the benefits arising out of such activities if they originated a finished product or reproductive resources.

The Q&A gives a high level overview of key issues including patents, trade marks, competition law, patent licensing, generic entry, abuse of dominance and parallel imports.

A Q&A guide to medicinal product regulation and product liability law in Brazil.

On August 8 2017 ANVISA officially published the new Rule RDC Nº 168, related to the prior consent of the Agency on patent applications for pharmaceutical products and processes, regulated by Joint Ordinance ANVISA-INPI No. 1, dated April 12, 2017, aiming to a more efficient way to analyze patent applications.

ANVISA has published, on 08/02/2017, in the Federal Register, the the Public Consultation 371/2017 to discuss the extension, from 5 to 10 … Medical Devices – ANVISA´s Public Consultation to extend the registration term

The Ministry of Industry and Commerce (MDIC) and the Brazilian Patent and Trademark Office (INPI) have opened for Public Consultation a Proposal for a Resolution to regulate a simplified allowance procedure for patent applications in Brazil, aiming to deal in a swift manner with the ever increasing backlog of patent applications awaiting examination, currently exceeding the figure of 230.000.

The Ministry of Industry and Commerce (MDIC) and the Brazilian Patent and Trademark Office (INPI) have opened for Public Consultation a Proposal for a Resolution to regulate a simplified allowance procedure for patent applications in Brazil, aiming to deal in a swift manner with the ever increasing backlog of patent applications awaiting examination, currently exceeding the figure of 230.000.

Allergan had obtained an injunction preventing the marketing of a generic drug for Combingan®. However, such injunction was revoked because the Trial … São Paulo Court allows the marketing of generic drug while the patent applications for the reference drug are still pending